Cargando…

Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity

Non-small cell lung cancer (NSCLC), one of the leading causes of cancer-related death, has a low 5-year survival rate owing to the inevitable acquired resistance toward antitumor drugs, platinum-based chemotherapy, and targeted therapy. Epidermal growth factor (EGF)-EGF receptor (EGFR) signaling act...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mi Seong, Kim, So Hui, Yang, Sei Hoon, Kim, Min Seuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447054/
https://www.ncbi.nlm.nih.gov/pubmed/32841278
http://dx.doi.org/10.1371/journal.pone.0238155
_version_ 1783574235686371328
author Kim, Mi Seong
Kim, So Hui
Yang, Sei Hoon
Kim, Min Seuk
author_facet Kim, Mi Seong
Kim, So Hui
Yang, Sei Hoon
Kim, Min Seuk
author_sort Kim, Mi Seong
collection PubMed
description Non-small cell lung cancer (NSCLC), one of the leading causes of cancer-related death, has a low 5-year survival rate owing to the inevitable acquired resistance toward antitumor drugs, platinum-based chemotherapy, and targeted therapy. Epidermal growth factor (EGF)-EGF receptor (EGFR) signaling activates downstream events leading to phospholipase C/inositol trisphosphate (IP(3))/Ca(2+) release from IP(3)-sensitive Ca(2+) stores to modulate cell proliferation, motility, and invasion. However, the role of EGFR-mediated Ca(2+) signaling in acquired drug resistance is not fully understood. Here, we analyzed alterations of intracellular Ca(2+) ([Ca(2+)]i) responses between gefitinib-sensitive NSCLC PC-9 cells and gefitinib-resistant NSCLC PC-9/GR cells, and we found that acute EGF treatment elicited intracellular Ca(2+) ([Ca(2+)]i) oscillations in PC-9 cells but not in PC-9/GR cells. PC-9/GR cells presented a more sustained basal [Ca(2+)]i level, lower endoplasmic reticulum Ca(2+) level, and higher spontaneous extracellular Ca(2+) ([Ca(2+)]e) influx than PC-9 cells. Notably, restricting [Ca(2+)]e in both cell types induced identical [Ca(2+)]i oscillations, dependent on phospholipase C and EGFR activation. Consequently, restricting [Ca(2+)]e in PC-9/GR cells upregulated gefitinib-mediated poly (ADP-ribose) polymerase cleavage, an increase in Bax/Bcl-2 ratio, cytotoxicity, and apoptosis. In addition, nuclear factor of activated T cell (NFAT1) induction in response to EGF was inhibited by gefitinib in PC-9 cells, whereas EGF-mediated NFAT1 induction in PC-9/GR cells was sustained regardless of gefitinib treatment. Restricting [Ca(2+)]e in PC-9/GR cells significantly reduced EGF-mediated NFAT1 induction. These findings indicate that spontaneous [Ca(2+)]e influx in NSCLC cells plays a pivotal role in developing acquired drug resistance and suggest that restricting [Ca(2+)]e may be a potential strategy for modulating drug-sensitivity.
format Online
Article
Text
id pubmed-7447054
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-74470542020-08-31 Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity Kim, Mi Seong Kim, So Hui Yang, Sei Hoon Kim, Min Seuk PLoS One Research Article Non-small cell lung cancer (NSCLC), one of the leading causes of cancer-related death, has a low 5-year survival rate owing to the inevitable acquired resistance toward antitumor drugs, platinum-based chemotherapy, and targeted therapy. Epidermal growth factor (EGF)-EGF receptor (EGFR) signaling activates downstream events leading to phospholipase C/inositol trisphosphate (IP(3))/Ca(2+) release from IP(3)-sensitive Ca(2+) stores to modulate cell proliferation, motility, and invasion. However, the role of EGFR-mediated Ca(2+) signaling in acquired drug resistance is not fully understood. Here, we analyzed alterations of intracellular Ca(2+) ([Ca(2+)]i) responses between gefitinib-sensitive NSCLC PC-9 cells and gefitinib-resistant NSCLC PC-9/GR cells, and we found that acute EGF treatment elicited intracellular Ca(2+) ([Ca(2+)]i) oscillations in PC-9 cells but not in PC-9/GR cells. PC-9/GR cells presented a more sustained basal [Ca(2+)]i level, lower endoplasmic reticulum Ca(2+) level, and higher spontaneous extracellular Ca(2+) ([Ca(2+)]e) influx than PC-9 cells. Notably, restricting [Ca(2+)]e in both cell types induced identical [Ca(2+)]i oscillations, dependent on phospholipase C and EGFR activation. Consequently, restricting [Ca(2+)]e in PC-9/GR cells upregulated gefitinib-mediated poly (ADP-ribose) polymerase cleavage, an increase in Bax/Bcl-2 ratio, cytotoxicity, and apoptosis. In addition, nuclear factor of activated T cell (NFAT1) induction in response to EGF was inhibited by gefitinib in PC-9 cells, whereas EGF-mediated NFAT1 induction in PC-9/GR cells was sustained regardless of gefitinib treatment. Restricting [Ca(2+)]e in PC-9/GR cells significantly reduced EGF-mediated NFAT1 induction. These findings indicate that spontaneous [Ca(2+)]e influx in NSCLC cells plays a pivotal role in developing acquired drug resistance and suggest that restricting [Ca(2+)]e may be a potential strategy for modulating drug-sensitivity. Public Library of Science 2020-08-25 /pmc/articles/PMC7447054/ /pubmed/32841278 http://dx.doi.org/10.1371/journal.pone.0238155 Text en © 2020 Kim et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kim, Mi Seong
Kim, So Hui
Yang, Sei Hoon
Kim, Min Seuk
Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
title Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
title_full Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
title_fullStr Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
title_full_unstemmed Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
title_short Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
title_sort restricting extracellular ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated ca(2+) response, which consequently enhances gefitinib sensitivity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447054/
https://www.ncbi.nlm.nih.gov/pubmed/32841278
http://dx.doi.org/10.1371/journal.pone.0238155
work_keys_str_mv AT kimmiseong restrictingextracellularca2ongefitinibresistantnonsmallcelllungcancercellsreversesalteredepidermalgrowthfactormediatedca2responsewhichconsequentlyenhancesgefitinibsensitivity
AT kimsohui restrictingextracellularca2ongefitinibresistantnonsmallcelllungcancercellsreversesalteredepidermalgrowthfactormediatedca2responsewhichconsequentlyenhancesgefitinibsensitivity
AT yangseihoon restrictingextracellularca2ongefitinibresistantnonsmallcelllungcancercellsreversesalteredepidermalgrowthfactormediatedca2responsewhichconsequentlyenhancesgefitinibsensitivity
AT kimminseuk restrictingextracellularca2ongefitinibresistantnonsmallcelllungcancercellsreversesalteredepidermalgrowthfactormediatedca2responsewhichconsequentlyenhancesgefitinibsensitivity